Equities Analysts Offer Predictions for BHC FY2025 Earnings

Bausch Health Companies Inc. (NYSE:BHC) – Stock analysts at Zacks Research dropped their FY2025 earnings per share estimates for Bausch Health Companies in a research note issued on Monday, January 20th. Zacks Research analyst R. Department now anticipates that the company will post earnings per share of $4.23 for the year, down from their previous estimate of $4.28. The consensus estimate for Bausch Health Companies’ current full-year earnings is $3.73 per share. Zacks Research also issued estimates for Bausch Health Companies’ Q4 2026 earnings at $1.27 EPS and FY2026 earnings at $4.90 EPS.

Other research analysts have also issued reports about the company. StockNews.com upgraded Bausch Health Companies from a “hold” rating to a “buy” rating in a research note on Friday, October 25th. Evercore ISI raised shares of Bausch Health Companies to a “hold” rating in a report on Tuesday, October 15th. Finally, Royal Bank of Canada raised their price target on shares of Bausch Health Companies from $10.00 to $11.00 and gave the stock a “sector perform” rating in a research note on Friday, November 1st. One research analyst has rated the stock with a sell rating, five have assigned a hold rating and two have given a buy rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Hold” and a consensus target price of $7.75.

Bausch Health Companies Trading Up 3.4 %

NYSE BHC opened at $7.73 on Thursday. Bausch Health Companies has a twelve month low of $3.96 and a twelve month high of $11.46. The firm has a 50-day simple moving average of $7.86 and a 200 day simple moving average of $7.45.

Bausch Health Companies (NYSE:BHC) last announced its quarterly earnings data on Wednesday, October 30th. The company reported $1.12 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.02 by $0.10. Bausch Health Companies had a negative net margin of 1.88% and a negative return on equity of 755.86%. The business had revenue of $2.51 billion for the quarter, compared to the consensus estimate of $2.42 billion. During the same quarter last year, the company posted $1.03 earnings per share. Bausch Health Companies’s quarterly revenue was up 12.2% on a year-over-year basis.

Institutional Investors Weigh In On Bausch Health Companies

Several hedge funds have recently bought and sold shares of the company. DGS Capital Management LLC bought a new stake in Bausch Health Companies in the fourth quarter valued at approximately $143,000. Merit Financial Group LLC bought a new stake in Bausch Health Companies in the 4th quarter valued at $228,000. Sanders Morris Harris LLC increased its holdings in shares of Bausch Health Companies by 16.0% in the fourth quarter. Sanders Morris Harris LLC now owns 28,975 shares of the company’s stock valued at $234,000 after purchasing an additional 4,000 shares during the last quarter. Northwest & Ethical Investments L.P. raised its position in shares of Bausch Health Companies by 13.0% in the third quarter. Northwest & Ethical Investments L.P. now owns 32,384 shares of the company’s stock valued at $264,000 after purchasing an additional 3,734 shares during the period. Finally, Creative Planning boosted its holdings in shares of Bausch Health Companies by 16.9% during the 3rd quarter. Creative Planning now owns 55,351 shares of the company’s stock worth $452,000 after buying an additional 7,995 shares during the period. 78.65% of the stock is currently owned by institutional investors and hedge funds.

Bausch Health Companies Company Profile

Bausch Health Companies Inc operates as a diversified specialty pharmaceutical and medical device company in the United States and internationally. It develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals, over-the-counter (OTC) products, aesthetic medical devices, and eye health.